Therabron Therapeutics and the NIH’s National Cancer Institute have entered into a Cooperative Research and Development Agreement (CRADA) in order to perform research on another member of the secretoglobin family called SCGB3A2.  The title of the CRADA is; “Development of recombinant human secretoglobin 3A2 (SCGB3A2) as a biologic drug candidate: characterization of fundamental properties.”  CC10, also known as SCGB1A1, and SCGB3A2 are members of the same family of proteins that share a similar structure and have many properties in common.  Due to the company’s extensive know-how acquired in developing CC10, it is well-positioned to develop SCGB3A2 as a new drug candidate.  The duration of the CRADA is 2.5 years, during which the company will produce the recombinant protein and characterize its properties in vitro, and the NCI will evaluate the recombinant protein in its specialized animal models of lung development and disease.